EQS-News: Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout Blue March 2023

Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout Blue March 2023   

Mainz Biomed to host several events for patients and healthcare professionals in Germany to increase awareness about the importance of early detection of colorectal cancer. 

BERKELEY, US MAINZ, Germany March 1, 2023  Mainz Biomed NV (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, joins advocacy organizations around the world in recognizing Colorectal Cancer Awareness Month in March. Colorectal cancer is the third most common cancer globally, with more than 1.9 million new cases in 2020. This year, Mainz Biomed will be hosting several educational and training events throughout Germany to raise awareness of the importance of early detection.

We have developed these events to support the colorectal cancer community, as this disease is the third most common cancer globally and the fourth leading cause of cancer death in the US, said Guido Baechler, Chief Executive Officer of Mainz Biomed. Our goal is to reduce these statistics and save lives by raising awareness about the simplicity and efficacy of using at-home CRC detection kits, like ColoAlert. Our non-invasive DNA stool test allows people to screen themselves in the comfort of their own home and then receive a follow-up notification from their physician to discuss results and next steps.

Upcoming Colorectal Cancer Awareness Month Events

Professionals

Training Sessions for gastroenterologists, healthcare providers
Gastro-Update Conference;
#1 Friday and Saturday, March 10-11, 2023 (Time TBD)
Rheingoldhalle; Mainz
#2 Friday and Saturday, March 24-25, 2023 (Time TBD)
Berlin Congress Center; Berlin/Livestream

Public

Educational Event for patients, families, caregivers, advocates
Saturday, March 11, 2023 (09:00-16:00)
(Outdoor event venue TBD); Mainz Altstadt

Mainz Biomed invites others to further amplify awareness of CRC by using the #BlueForCRC and #CRCAwareness hashtags on social media and going blue on Friday, March 3 by dressing in blue!

 About ColoAlert

ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy (Dollinger MM et al., 2018). The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT). It is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVDR marked (complying with EU safety, health and environmental requirements) and commercially available in a selection of countries in the European Union and the United Arab Emirates. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. If approved in the United States, the Companys commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.

About Colorectal Cancer
According to the Centers for Disease Control and Prevention (CDC), CRC is the second most lethal cancer in the United States and Europe, but also the most preventable, with early detection providing survival rates above 90%. The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the US, with 52,980 resulting in death. Recent decisions by the U.S. Food and Drug Administration (FDA) suggest that screening with stool DNA tests such as ColoAlert in the United States should be conducted once every three years starting at age 45. Currently, there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years and a US market opportunity of approximately $3.7 billion per year.

About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Companys flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for CRC. ColoAlert is currently marketed across Europe and in select international territories. The Company is currently running a pivotal FDA clinical study for U.S. regulatory approval. Mainz Biomeds product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time PCR multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook. 

For media inquiries, please contact press@mainzbiomed.com 
In Europe:
MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu

In the US:
Spectrum Science
Melissa Laverty/Valerie Enes
+1 540 272 6465
mainz@spectrumscience.com

For investor inquiries, please contact info@mainzbiomed.com

Forward-Looking Statements

Certain statements made in this press release are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as anticipate, believe, expect, estimate, plan, outlook, and project and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Companys expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the SEC) by the Company. Additional information concerning these and other factors that may impact the Companys expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on May 5, 2022. The Companys SEC filings are available publicly on the SECs website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly. update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.